Preclinical Evaluation Study of 68 Ga-Labeled PSMA-Targeted Dimer Probe
Chemical & Biomedical Imaging · 2026-01-26 · 4 (1) · 54-63
DOI: 10.1021/cbmi.5c00048 ↗At a glance
Journal article in Chemical & Biomedical Imaging, published online on 2025-07-10. Written by Quan Xie and 8 co-authors. Institution: School of Pharmacy, Nanjing Medical University, Nanjing 211166, China. Cited 6 times so far (Crossref); 44 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Natural Science Foundation of Jiangsu Province, Jiangsu Commission of Health.
Abstract (original language)
The development of tracers targeting prostate-specific membrane antigen (PSMA) has great significance for improving the diagnosis and treatment of prostate cancer (PCa). In this study, a dimeric PSMA-targeting ligand, PSMA-DIM, has been designed and synthesized based on the structure of the Glu-urea-Lys pharmacophore by introducing 4-(p-iodophenyl) butyric acid and PEG4 motifs. [ 68 Ga]-Ga-PSMA-DIM exhibited high radiochemical purity (>98%) and stability, with a K d value for LNCaP cells of 37.09 ± 13.53 nM. The uptake and internalization of [ 68 Ga]-Ga-PSMA-DIM by LNCaP cells were significantly higher compared to 22Rv1 or PC-3 cells. The elimination half-life of [ 68 Ga]-Ga-PSMA-DIM from the plasma was calculated to be 99.55 min, indicating a significant extension of retention time in vivo. The peak tumor uptake of [ 68 Ga]-Ga-PSMA-DIM in LNCaP and 22Rv1 tumor-bearing mice was 4.19 ± 0.65 %ID/mL and 4.08 ± 0.47 %ID/mL, respectively, which was significantly higher than that observed in the PC-3 tumor-bearing mice (2.71 ± 0.70 %ID/mL). Moreover, [ 68 Ga]-Ga-PSMA-DIM maintained relatively high uptake in LNCaP and 22Rv1 tumors even after 3 h (3.84 ± 0.50 %ID/mL and 3.59 ± 0.57 %ID/mL, respectively). In conclusion, [ 68 Ga]-Ga-PSMA-DIM could sensitively and specifically differentiate models with varying PSMA expression levels and show notable retention in vivo.
Subjects
Author keywords
Authors and institutions
- School of Pharmacy, Nanjing Medical University, Nanjing 211166, China.
- NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China.
ORCID profiles: Jianguo Lin
Funding
- Natural Science Foundation of Jiangsu Province
- Jiangsu Commission of Health
Cite
APA
Xie, Q., Yang, J., Li, J., Qin, J., Tang, R., Zhao, J., Peng, Y., Qiu, L., & Lin, J. (2026). Preclinical Evaluation Study of 68 Ga-Labeled PSMA-Targeted Dimer Probe. Chemical & Biomedical Imaging, 4(1), 54-63. https://doi.org/10.1021/cbmi.5c00048
Vancouver
Xie Q, Yang J, Li J, Qin J, Tang R, Zhao J, et al. Preclinical Evaluation Study of 68 Ga-Labeled PSMA-Targeted Dimer Probe. Chemical & Biomedical Imaging. 2026;4(1):54-63. doi:10.1021/cbmi.5c00048
BibTeX
@article{Xie2026,
author = {Xie, Quan and Yang, Jichen and Li, Jing and Qin, Jiawen and Tang, Rui and Zhao, Jun and Peng, Ying and Qiu, Ling and Lin, Jianguo},
title = {Preclinical Evaluation Study of 68 Ga-Labeled PSMA-Targeted Dimer Probe},
journal = {Chemical & Biomedical Imaging},
year = {2026},
volume = {4},
number = {1},
pages = {54--63},
doi = {10.1021/cbmi.5c00048}
}
EUVIMED